Key result
Treatment with spironolactone in women with PCOS significantly increased large artery elasticity (P=0.047) and decreased systemic vascular resistance (P=0.0005).
Why the study?
Does spironolactone improve vascular compliance and elasticity in women with polycystic ovary syndrome?
Observational (n=10)
Does spironolactone improve vascular compliance and elasticity in women with polycystic ovary syndrome?
Spironolactone improves large artery elasticity and reduces systemic vascular resistance in women with PCOS, suggesting potential favorable effects on vascular health.
Answers are grounded in this paper and cite their sources.
May support vascular benefits of spironolactone in PCOS; leaves open need for RCTs before practice change.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age in the United States and has been associated with several diseases including cardiovascular disease, obesity, and glucose intolerance. In this study, systolic blood pressure, diastolic blood pressure, pulse pressure (vascular compliance), large artery elasticity, systemic vascular resistance (SVR), total vascular impedance (TVI), and body mass index (BMI) were measured before and after treatment with spironolactone in 10 women with PCOS. Systolic BP, diastolic BP, and BMI were similar prior to treatment and after treatment. Pulse pressure decreased slightly post-treatment compared to pretreatment but not to significance (P = 0.07). The results show that after treatment with spironolactone, there was a statistically significant increase in large artery elasticity (P = 0.047), while there was a statistically significant decrease in SVR and TVI (P = 0.0005 and P = 0.03). This study indicates that treatment with spironolactone improves large artery elasticity and reduces systemic vascular resistance without any change in small artery elasticity.
No takes yet. Share an insight, caveat, or question.
Muneyyirci‐Delale et al. (2018) conducted an observational in Polycystic ovary syndrome (n=10). Spironolactone vs. Pretreatment baseline was evaluated on Large artery elasticity (p=0.047). Treatment with spironolactone in women with PCOS significantly increased large artery elasticity (P=0.047) and decreased systemic vascular resistance (P=0.0005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: